Literature DB >> 6446878

Comparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics.

B R Meyers, S Z Hirschman, L Strougo, E Srulevitch.   

Abstract

Piperacillin, ticarcillin, and carbenicillin were administered intravenously to 10 healthy volunteers in a three-way, crossover study. The pharmacokinetics of the three drugs were in general quite similar. The peak serum concentration of piperacillin achieved at the end of a 30-min intravenous infusion was 63.5 +/- 27.6 microgram/ml. During the first 8 h, 67.5% of the dose of piperacillin was excreted in the urine, and the urinary concentration was extremely high. All three penicillins had high volumes of distribution. The serum half-life of the beta elimination phase of carbenicillin was lower than that of either piperacillin or ticarcillin. The volunteers experienced no adverse reactions from the administration of the drugs.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6446878      PMCID: PMC283839          DOI: 10.1128/AAC.17.4.608

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Sensitivity of Pseudomonas aeruginosa to antibiotics: emergence of strains highly resistant to carbenicillin.

Authors:  E J Lowbury; H A Lilly; A Kidson; G A Ayliffe; R J Jones
Journal:  Lancet       Date:  1969-08-30       Impact factor: 79.321

3.  Carbenicillin therapy for pseudomonas infections.

Authors:  G P Bodey; J P Whitecar; E Middleman; V Rodriguez
Journal:  JAMA       Date:  1971-10-04       Impact factor: 56.272

4.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

5.  Bacteriological, pharmacological, and clinical studies of carbenicillin.

Authors:  B R Meyers; J Sabbaj; L Weinstein
Journal:  Arch Intern Med       Date:  1970-02

6.  In vitro and in vivo antibacterial activity of T-1220, a new semisynthetic penicillin.

Authors:  K Ueo; Y Fukuoka; T Hayashi; T Yasuda; H Taki; M Tai; Y Watanabe; I Saikawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

7.  Comparative in vitro activity and clinical pharmacology of ticarcillin and carbenicillin.

Authors:  H C Neu; G J Garvey
Journal:  Antimicrob Agents Chemother       Date:  1975-10       Impact factor: 5.191

8.  Ticarcillin vs carbenicillin: clinical pharmacokinetics.

Authors:  R D Libke; J T Clarke; E D Ralph; R P Luthy; W M Kirby
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

9.  Metabolism of penicillins to penicilloic acids and 6-aminopenicillanic acid in man and its significance in assessing penicillin absorption.

Authors:  M Cole; M D Kenig; V A Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

10.  Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288).

Authors:  V Rodriguez; J Inagaki; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1973-07       Impact factor: 5.191

View more
  14 in total

1.  Comparative pharmacokinetics of apalcillin and piperacillin.

Authors:  H Lode; A Elvers; P Koeppe; K Borner
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

2.  High-performance liquid chromatographic determination of piperacillin in plasma.

Authors:  A M Brisson; J B Fourtillan
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

3.  Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers.

Authors:  B R Meyers; E S Srulevitch; J Jacobson; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

Review 4.  Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors:  R de Groot; A L Smith
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

6.  Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age.

Authors:  Dagan O Lonsdale; Emma H Baker; Karin Kipper; Charlotte Barker; Barbara Philips; Andrew Rhodes; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2018-11-26       Impact factor: 4.335

7.  Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration.

Authors:  Kook-Hwan Oh; Chiweon Kim; Hankyu Lee; Hajeong Lee; Ji Yong Jung; Nam Joong Kim; Kyung-Sang Yu; Kwang-Hee Shin; In-Jin Jang; Curie Ahn
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

8.  Plasma levels of piperacillin and vancomycin used as prophylaxis in liver transplant patients.

Authors:  M Dupon; G Janvier; G Vinçon; S Winnock; F Demotes-Mainard; O Capeyron; J Saric
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Stereoselective renal tubular secretion of carbenicillin.

Authors:  T Itoh; M Ishida; Y Onuki; Y Tsuda; H Shimada; H Yamada
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

10.  Applications of minimal physiologically-based pharmacokinetic models.

Authors:  Yanguang Cao; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-23       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.